Marwa Nadia Rahimi

Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

Marwa Nadia Rahimi, Jo‐Anne Pinson, J.P. Hilton-Proctor, Jessica Van Zuylekom et autres

R-targeted therapy, addressing current limitations and providing an improved treatment option for neuroendocrine tumors with substantially enhanced therapeutic outcomes.

au (code pays fourni par la source)

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

Marwa Nadia Rahimi, Jo‐Anne Pinson, J.P. Hilton-Proctor, Jessica Van Zuylekom et autres

Correction for ‘Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting’ by Marwa N. Rahimi et al. , RSC Adv. , 2026, 16 , 2123–2132, https://doi.org/10.1039/D5RA08789A.

au (code pays fourni par la source)

Radiolabelled peptides targeting CXCR4 for cancer imaging and treatment

Abdullah M. S. Al‐Osaimi, Amarachi Amah, Marwa Nadia Rahimi, Peter D. Roselt et autres

au (code pays fourni par la source)

Dual Function, Singular Impact: Successes of a Novel Class of Theranostic Gastramide (GA) Peptides Targeting Cholecystokinin-2 Receptor

Marwa Nadia Rahimi, Jessica Van Zuylekom, Benjamin J. Blyth, Peter D. Roselt et autres

au (code pays fourni par la source)

Precision peptide theranostics: developing N- to C-terminus optimized theranostics targeting cholecystokinin-2 receptor

Marwa Nadia Rahimi, Alicia Corlett, Jessica Van Zuylekom, Marc‐Antoine Sani et autres

Peptides are ideal for theranostic development as they afford rapid target accumulation, fast clearance from background tissue, and exhibit good tissue penetration.Previously, we developed a novel series of peptides that presented discreet folding propensity leading to an optimal candidate [ 68 Ga]Ga-DOTA-GA1 …

au (code pays fourni par la source)

First-In-Class Diagnostics Targeting Neuropeptide Y1 Receptor (Y1R): Enabling Molecular Imaging of Metastatic Breast Cancer

Marwa Nadia Rahimi, Jessica Van Zuylekom, Neale Scott Mason, Benjamin J. Blyth et autres

The Next Generation of Tumour Homing Peptides: Foldamers at the Forefront of Precise Cancer Theranostics

Marwa Nadia Rahimi, Alicia Corlett, Jessica Van Zuylekom, Peter D. Roselt et autres

Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers

Alicia Corlett, Jo‐Anne Pinson, Marwa Nadia Rahimi, Jessica Van Zuylekom et autres

Peptide receptor radionuclide therapy (PRRT) is a promising form of systemic radiation therapy designed to eradicate cancer. Cholecystokinin-2 receptor (CCK 2 R) is an important molecular target that is highly expressed in a range of cancers. This study describes the synthesis and …

au (code pays fourni par la source)

Structure-activity relationship study of peptide Gastramide-01 (GA-01), a potent binder of cholecystokinin-2 (CCK-2) receptor and theranostic candidate

Marwa Nadia Rahimi, Alicia Corlett, Jessica Van Zuylekom, Benjamin J. Blyth et autres

Frontispiece: Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development

Laura K. Buckton, Marwa Nadia Rahimi, Shelli R. McAlpine

In their review article on page 1487, S. R. McAlpine et al., describe recent strategies used to develop cell permeable cyclic peptides that retain binding to their biological target once inside the cell. They discuss chemical strategies that have produced molecules with …

au (code pays fourni par la source)

Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development

Laura K. Buckton, Marwa Nadia Rahimi, Shelli R. McAlpine

Developing macrocyclic peptides that can reach intracellular targets is a significant challenge. This review discusses the most recent strategies used to develop cell permeable cyclic peptides that maintain binding to their biological target inside the cell. Macrocyclic peptides are unique from small …

au (code pays fourni par la source)

Delivering bioactive cyclic peptides that target Hsp90 as prodrugs

Yuantao Huo, Laura K. Buckton, Jack L. Bennett, Eloise C. Smith et autres

The most challenging issue facing peptide drug development is producing a molecule with optimal physical properties while maintaining target binding affinity. Masking peptides with protecting groups that can be removed inside the cell, produces a cell-permeable peptide, which theoretically can maintain its …

au (code pays fourni par la source)